Login    Join free Add to favorites    中文
home > news > EKF Diagnostics鈥 Novel Diabetic Biomarker Test Successfully Externally Verified
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
EKF Diagnostics鈥 Novel Diabetic Biomarker Test Successfully Externally Verified

hits:554     Date:10/19/16
Glycated Serum Protein assay provides simple, sensitive and fast alternative
glycemic monitoring test
                                                                      
Cardiff, UK 鈥 18th October 2016 鈥 EKF Diagnostics, the global in vitro diagnostics company, announces that its newly introduced Glycated Serum Protein (GSP) LiquiColor® diabetic biomarker test has been verified for use on the Siemens Vista chemistry analyzer. In a scientific poster published by scientists at the Memorial Healthcare System, Hollywood, USA [1], it was demonstrated that EKF鈥檚 GSP assay enhances the versatility of the Vista system for the specialized glycemic monitoring of diabetics with hemoglobinopathies, or conditions that affect red blood cell (RBC) lifespan.
 
Daily blood glucose and HbA1c are used as short and long term (3-4 month) measures of glycemic control respectively. However, HbA1c values may be adversely affected by patients with hemoglobin variants or conditions that affect RBC lifespan such as anemia and dialysis to name a few, while GSP as a 2-3 week indicator of blood glucose, is unaffected. Traditional NBT assays for fructosamine (or GSP), used as an alternative test for diabetes patients with hemoglobinopathies and pregnant women, suffer from a variety of interferences. Due to these analytical issues, the Memorial Healthcare System scientists required a reliable alternative that could be adapted to their existing analyzer. Therefore, the EKF Diagnostics GSP assay was evaluated and validated using an open channel user defined method.
 
EKF鈥檚 GSP assay bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured
 
EKF鈥檚 GSP assay bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured
 
The scientific poster authors concluded that EKF鈥檚 GSP assay provides laboratories with a simple, sensitive and fast alternative glycemic monitoring test without the endogenous substance interference that are typically observed in NBT based colorimetric assays.   
 
鈥淲e are pleased with the recognition by the Memorial Health System of the value of our GSP diabetic biomarker test which is based on a double enzymatic degradation method. This provides superior specificity, accuracy and reliability compared to the older non-enzymatic fructosamine NBT method,鈥 said Al Blanco, Business Unit Director 鈥 Central Lab at EKF Diagnostics.
 
He added, 鈥淎s a 2-3 week indicator of average blood glucose which is unaffected by RBC half-life, GSP closes the information gap between daily blood glucose and HbA1c testing. This means that GSP serves as an accurate intermediate marker of glycemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and hemodialysis.鈥
 
The Memorial Health System scientific poster presented at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting 2016 is available to view at: http://www.ekfdiagnostics.com/glycated-serum-protein.html.
 
For more information on EKF Diagnostics, please see www.ekfdiagnostics.com.
 
Reference
  1. Chittiprol S., Buzaki C., Tinckell H., Kiechle F.L. Validation of a new Glycated Serum Protein assay on the Siemens Vista analyzer. American Association for Clinical Chemistry (AACC) Annual Scientific Meeting - Scientific Poster Presentation (2016).
About EKF Diagnostics - www.ekfdiagnostics.com
EKF Diagnostics Holdings plc, which includes the Stanbio Chemistry brand, specializes in the development, production and worldwide distribution of point-of-care analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.
 
Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
 
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents, as well as associated analyzers. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.
Related News>> more
advertisement

Copyright(C) 2006-2017 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙